Lipid-Engineered Small-Sized Metal-Organic Frameworks for Targeted Delivery of Anlotinib in Lung Cancer Treatment
A specially designed nanoparticle delivers lung cancer drugs more precisely to tumors while sparing healthy tissue in animal models.
This preclinical study designs and evaluates a biomimetic liposome-coated metal-organic framework (Anlo@MOF-Lipo) for targeted delivery of anlotinib in lung cancer, combining tumor-responsive drug release with oxidative stress induction. In both subcutaneous and orthotopic murine models, the nanocarrier outperformed free anlotinib with no observable systemic toxicity.
What the study was
- Study design
- Preclinical experimental (in vitro + murine xenograft model)
- Population
- Lung cancer cell lines + murine subcutaneous/orthotopic tumor models
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- International Journal of Nanomedicine
Why it surfaced
Interesting drug delivery innovation but purely preclinical (animal model only); capped at score 5 per non-human rule. Novel dual-mechanism platform but no human data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.